The Third Circuit Court of Appeals has issued a significant ruling in the case of Sandoz Inc. v. United Therapeutics Corporation, Docket No. 24-3067, reversing earlier decisions made by a lower court. The case centers on competitive practices between two pharmaceutical companies regarding the drug treprostinil, which is used to treat pulmonary arterial hypertension. This ruling affects not only the companies involved but also has broader implications for the pharmaceutical industry and competition among drug manufacturers.
In this case, Sandoz Inc. and RareGen, LLC, claimed that United Therapeutics Corporation (UTC) engaged in unfair practices that violated federal antitrust laws and breached a patent settlement agreement. The dispute began when Sandoz received approval to market a generic version of treprostinil, which UTC had initially developed and marketed under the brand name Remodulin. The case highlights the tension between brand-name and generic drug manufacturers and the legal complexities that arise from patent agreements and market competition.
United Therapeutics launched Remodulin in 2002, while Sandoz received approval for its generic version in 2017. Sandoz and RareGen allege that UTC violated their settlement agreement by taking actions that restricted the launch of their generic drug. The case was filed in the U.S. District Court for the District of New Jersey, where Judge Brian R. Martinotti presided over the initial proceedings.
The court ruled in favor of Sandoz on some claims, granting them a summary judgment on a breach-of-contract claim, but dismissed the antitrust and state tort claims against UTC. Sandoz was awarded over $61 million in damages. However, UTC appealed the decision, arguing that the lower court erred in its interpretation of the settlement agreement and the dismissal of the antitrust claims.
In its recent ruling, the Third Circuit Court of Appeals reversed the lower court's summary judgment in favor of Sandoz regarding the breach-of-contract claim. The court stated, "Because the settlement agreement does not unambiguously establish the interpretation that Sandoz advances, we will reverse the grant of summary judgment in favor of Sandoz as to liability on the breach-of-contract claim and remand with instructions that the issue of liability proceed to trial." The court also reversed the dismissal of the tortious interference claim against UTC, allowing that matter to be analyzed separately from the antitrust claims.
However, the court upheld the dismissal of the antitrust claims, affirming that UTC provided valid procompetitive justifications for its actions. The ruling stated, "As UTC demonstrated procompetitive justifications for its conduct, we will affirm the dismissal of the antitrust and state tort claims against UTC." This part of the ruling emphasizes the importance of competition in the pharmaceutical market and the legal protections that exist for companies engaging in competitive practices.
The impact of this ruling is significant for both Sandoz and United Therapeutics, as it alters the legal landscape surrounding their competition. The reversal of the breach-of-contract summary judgment means that Sandoz will have to prove its claims at trial, potentially leading to further legal battles and uncertainties. For UTC, the affirmation of its antitrust defenses reinforces its position in the market against generic competitors.
Moving forward, this case may set a precedent for how similar disputes are handled in the pharmaceutical industry, particularly regarding the interpretation of settlement agreements and the application of antitrust laws. The ruling could influence how pharmaceutical companies approach their agreements and competitive strategies in the future.
As for what’s next, the case is now sent back to the lower court for further proceedings regarding the breach-of-contract and tortious interference claims. It remains to be seen whether either party will seek further appeals on the antitrust claims or if there are related cases pending that could impact this ruling.